Genprex (GNPX) Stock Receives Validation From Independent Researchers

Genprex GNPX Stock News

Genprex Inc (NASDAQ: GNPX) issued big news today. According to the release, independent researches recently reported positive results from a study of TUSC2, the active agent in the company’s candidate, Oncoprex. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GNPX Stock Could See Strong Value Growth After Independent Research

In a press release issued early this morning, Genprex announced that independent researchers validated the work it is doing with Oncoprex. In the independent report associated with a recent study, the researchers found that TUSC2 prevented tumor growth in triple negative breast cancer.

As mentioned above, TUSC2 is the active ingredient in the company’s flagship candidate, Oncoprex. Moreover, triple negative breast cancer is a tough target to tackle. In fact, at the moment, this form of cancer is considered to be incurable and comes with limited therapeutic options.

Importantly, GNPX has no affiliation with the researchers that provided the report.

The study was published in the peer-reviewed journal, Nature. Through the study, researchers found MicroRNA-138 as a diagnostic market for TNBC. This specific type of cancer currently lacks therapeutic options as it does not express the estrogen and progesterone hormone receptors and human epidermal growth factor receptor 2.

In the release, GNPX said that TUSC2 was found to be a direct target of mIR-138, mimicing the effects of mIR-138 knockdown and preventing tumor growth.

At the moment, the company is conducting both clinical and pre-clinical research to evaluate the effectiveness of TUSC2 when combined with targeted therapies and immunotherapies in non-small cell lung cancer. However, existing data also suggest that the active ingredient in Oncoprex may be effective against various other types of cancer, including glioblastoma, head and neck cancer, kidney cancer, soft tissue sarcomas, and now the most aggressive subset of breast cancer.

In a statement, Rodney Varner, Chairman and CEO at GNPX, had the following to offer:

The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging. We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.

Why This Is Important

While Genprex is actively studying Oncoprex as an option in non-small cell lung cancer, the implications of a treatment that has the ability to tackle types of cancers that are difficult to treat are tremendous.

If you invest in clinical-stage oncology companies, you’re no stranger to the term triple negative breast cancer, or TNBC. At the end of the day, this is a very aggressive form of cancer that leaves patients with little to no options.

The fact that TUSC2, the active ingredient in Oncoprex, has shown signs of efficacy in this very difficult to treat indication is huge news. At the end of the day, the news issued adds a high value indication to the potential targets for the drug, expanding the long-term value of GNPX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

CNA Finance, parent company to Alpha Stock News, has been paid to cover Genprex news.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.